about
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testingCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaIL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy ResistanceClinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondMYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemiaClonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcomeMYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsWaldenström macroglobulinemia: from biology to treatment.MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Disease-specific mutations in mature lymphoid neoplasms: recent advances.Current and future therapeutic approach for Waldenström's macroglobulinemia.Molecular pathogenesis of CLL and its evolution.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?Pyrosequencing as a fast and reliable method in detecting the MYD88 p.L265P mutation in decalcified formalin-fixed and paraffin-embedded tissues.Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.An algorithmic approach to diagnose haematolymphoid neoplasms in effusion by combining morphology, immunohistochemistry and molecular cytogenetics.MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.Waldenström's macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection.Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia.MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
P2860
Q26784600-6FBBDFC8-D52F-45CE-854C-1599F7725FC9Q26851166-C9EE941B-5902-4507-9CF2-9948D8C83F57Q26866390-990B2622-09A7-44DD-865E-ED6B0F7D8893Q27027493-B7932CCF-61CB-4D63-B6C6-313BCA9837F6Q30459093-35002667-DD07-4652-9A03-E26F3D89C432Q33660823-64F7B207-0CD9-4D48-BEE9-C5B0EDDF4175Q34101118-6213F63F-E215-4D12-ABF6-21677631027DQ34435295-8BBE63F5-4931-4E1F-99EF-3711C651A5CFQ34803768-4EDF67ED-D448-4EE6-8E53-9D99AECA08B5Q36058393-0D9D6BCD-D3EE-4339-AEF7-19F573AA1A96Q37499211-8DBB2878-1A99-4072-811B-412EC29D87D2Q37621361-F85E4E18-1A9D-4FA1-820C-F2281CC878B1Q37711782-B1F58871-2BFC-456C-8308-7555AA68AAD4Q37723475-1B191187-D31D-4006-B628-84D714264662Q38115233-7CBA7AB2-2545-4EC1-AFFC-7B7E6141CE1EQ38150849-03E5C404-6E40-423A-BAE4-851CD41C2291Q38176969-FDB78FBE-5363-4DAD-96E9-EC22CEABC5C3Q38191449-AB0491FB-FC33-4A31-8978-88E714822A50Q38201143-E8ADBB2A-BF43-4346-9B5A-C21D06933BE8Q38206820-F9D04BE3-D3A9-49B5-8ED0-4961317D83FDQ38335695-E59D13B0-85A2-420F-97DA-D2FAA3BECF2FQ38760522-C8BA10F0-1863-4F3E-A08C-2A797E679AECQ38817771-E67A4EBC-9562-44E3-BECB-35670B250CBAQ38819164-A9A438F7-59A3-4290-9C29-C244F4690AA1Q38884712-87953202-E1D5-44CB-A711-D403BD491D0FQ38970612-E8F1CE9F-18A5-49DD-ACCE-6B2E8597F780Q39375290-CBEF07D1-25DC-4401-BF11-0B47800C807CQ41374007-B8942CB5-DCCE-4C79-AA12-BA73571D7FF5Q41863937-EFB27A31-A53E-4F3F-9624-56D1AAA5C1A8Q42415051-25C7B489-959B-4A16-8514-8798F46804D8Q42975466-55818360-41C4-4B0F-928E-496ED35BCB8CQ47140051-5820CD98-8558-40B0-8805-DD5A8DE0030BQ47686328-70402823-191C-4BB5-A09D-D3EB255EE0DAQ47697880-978F2034-A6A5-407D-BB4E-53171FB035E8Q47724587-1953E9BC-17F0-49A1-B62F-6A920ACEF172Q48101584-9CD8E344-E054-4590-9AA3-BF2906A28A6AQ48155069-69712538-B6B3-403E-B48A-21E311A3EF16Q48225458-5AFBCA09-83AA-44DB-BD60-B931389EB92CQ49372280-604035F4-CA0D-432D-B936-8057760545BCQ51626445-3C5A80AE-06A0-4773-BD97-3796189B1534
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@en
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@nl
type
label
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@en
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@nl
prefLabel
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@en
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
@nl
P2093
P50
P1433
P1476
MYD88 L265P mutation in Waldenstrom macroglobulinemia
@en
P2093
Agnès Daudignon
Aline Renneville
Audrey Decambron
Charles Herbaux
Christophe Roumier
Elisabeth Bertrand
Olivier Theisen
Patrick Duthilleul
Sabine Tricot
Sylvie Galiègue-Zouitina
P304
P356
10.1182/BLOOD-2012-06-436329
P407
P50
P577
2013-03-26T00:00:00Z